Ra Medical Systems to Report First Quarter 2021 Financial Results on May 11, 2021
April 19 2021 - 5:02PM
Business Wire
Ra Medical Systems, Inc. (NYSE American: RMED) announces that it
will report first quarter 2021 financial results after market close
on Tuesday, May 11, 2021. Ra Medical management will hold an
investment community conference call that day at 1:30 p.m. Pacific
time (4:30 p.m. Eastern time) to discuss financial results and
provide a company update.
Pre-Registration
Participants can pre-register for the
conference call here:
Callers who pre-register will be given a
conference passcode and unique PIN to gain immediate access to the
call and bypass the live operator. Participants may pre-register at
any time, including up to and after the call start time.
Live Call:
Those who choose not to pre-register can
access the live conference by dialing:
U.S.
866-777-2509
International
412-317-5413
Passcode
10155315
Live Webcast:
Ra Medical Website
The webcast will be archived for 30
days.
Replay:
U.S.
877-344-7529
Canada
855-669-9658
International
412-317-0088
Passcode
10155315
The replay will be available for 48
hours
Pursuant to the disclosure requirements of the NYSE American
Company Guidelines Sections 401(h) and 610(b), Ra Medical is
reporting that its audited financial statements for the fiscal year
ended December 31, 2020, included in Ra Medical’s Annual Report on
Form 10-K filed with the Securities and Exchange Commission on
March 17, 2021, contains an audit opinion from its independent
registered public accounting firm that includes an explanatory
paragraph related to Ra Medical’s ability to continue as a going
concern. This announcement does not represent any change or
amendment to the Company’s financial statements or to its Annual
Report on Form 10-K for the fiscal year ended December 31,
2020.
About Ra Medical Systems
Ra Medical Systems commercializes excimer lasers and catheters
for the treatment of vascular and dermatological diseases. In May
2017 the DABRA excimer laser system received FDA 510(k) clearance
in the U.S. for crossing chronic total occlusions, or CTOs, in
patients with symptomatic infrainguinal lower extremity vascular
disease with an intended use for ablating a channel in occlusive
peripheral vascular disease. The Pharos excimer laser system is
FDA-cleared and is used as a tool in the treatment of psoriasis,
vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are
both based on Ra Medical’s core excimer laser technology platform
and deploy similar mechanisms of action. Ra Medical manufactures
DABRA and Pharos excimer lasers and catheters in a
32,000-square-foot facility located in Carlsbad, Calif. The
vertically integrated facility is ISO 13485 certified and is
licensed by the State of California to manufacture sterile,
single-use catheters in controlled environments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210419005900/en/
At the Company: Andrew Jackson Chief Financial Officer,
Ra Medical Systems 760-496-9540 ajackson@ramed.com
Investors: LHA Investor Relations Jody Cain 310-691-7100
jcain@lhai.com
Ra Medical Systems (AMEX:RMED)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ra Medical Systems (AMEX:RMED)
Historical Stock Chart
From Sep 2023 to Sep 2024